Raleigh's Bryn Pharma – developing alternative to needles to fight deadly allergies- raises $11M

The company is working towards FDA approval of its epinephrine nasal spray, named UTULY, for treating anaphylaxis. If successful, it may replace the current anaphylaxis treatment standard, which is the needle-based EPIPEN.

Related Keywords

Jim Borneman ,Lisa Lucifero ,Steve Killmeyer ,Sandy Loreaux ,Steven Hartman ,Nurry Hong ,Business Development ,Bryn Pharma ,Chief Strategy ,Business Development Officer ,Chief Financial Officer ,Bryn Pharma Board ,